middle.news
Telix Secures UK Approval for Illuccix, Boosting Prostate Cancer Imaging Access
8:15am on Thursday 13th of February, 2025 AEDT
•
Biotechnology
Read Story
Telix Secures UK Approval for Illuccix, Boosting Prostate Cancer Imaging Access
8:15am on Thursday 13th of February, 2025 AEDT
Key Points
UK MHRA approves Illuccix for prostate cancer PSMA-PET imaging
Illuccix addresses critical supply shortages in UK and Europe
Local gallium-68 generator production enables flexible, rapid imaging
Exclusive UK distribution partnership established with Xiel Limited
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE